The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
The deal between the White House and Democrats was earlier expected to raise the debt ceiling for two years and permanently end the sequester.Politicsread more
The deal could be announced as soon as next week, according to the report.Technologyread more
President Donald Trump held "constructive" discussions on a range of economic issues including trade and national security issues.Technologyread more
Secretary of Education Betsy DeVos and her family have seen their investments skyrocket since President Donald Trump started enacting pro-business policies. Meanwhile, DeVos...Politicsread more
See which stocks are posting big moves after the bell on July 22.Market Insiderread more
The construction industry is heavily dependent on Hispanic and Latino workers, a workforce that diminished during the last housing crisis and has not come close to full...Real Estateread more
Former NFL offensive lineman Jeff Hatch, who had previously been candid about his own struggles with opioid addiction and substance abuse, pleaded guilty Friday to a drug...Politicsread more
U.S. stock futures were indicating a higher Wall Street open and a possible reversal of recent negative trends.Morning Briefread more
A group of gold miners stocks, "BAANG," are better plays than mega-cap FAANG names, according to John Roque, technical analyst at Wolfe Research.Marketsread more
Sanofi expects 2018 to mark a return to growth on the back of two recently announced acquisitions and a revamped pipeline, after it posted fourth-quarter profits slightly below expectations, hurt by a charge for its dengue vaccine.
France's largest drugmaker said on Wednesday that it forecast earnings per share growing between 2-5 percent at constant exchange rates this year, after a 0.4 percent drop in 2017.
Sanofi scored two big takeover deals last month, agreeing to buy U.S group Bioverativ for $11.6 billion and Belgium's Ablynx for 3.9 billion euros ($4.8 billion).
The company said it had recorded an impairment of tangible assets of 87 million euros related to Dengvaxia, its dengue vaccine currently at the centre of a health scare in the Philippines, in the fourth quarter.
Sanofi revealed in November that Dengvaxia — the world's first dengue vaccine — might increase the risk of severe disease in people who had never been exposed to the virus.
Fourth-quarter business net income fell 10.8 percent at constant exchange rates to 1.33 billion euros. Total sales rose 4.1 percent to 8.7 billion euros.
Analysts polled by Reuters in partnership with Inquiry Financial had on average been expecting business net profit of 1.46 billion euros and net sales of 8.7 billion.